A single arm phase II study of ADjuvant Endocrine therapy, subcutaneous Pertuzumab, and Trastuzumab fixed-dose combination for patients with anatomic stage I hormone receptor-positive, HER2-positive breast cancer (ADEPT)
| Protocol No. | CTO-20-347 | Scope | Local |
|---|---|---|---|
| Principal Investigator | Tarah Ballinger | Treatment Type | Treatment |
| Age Group | Adult | Phase | Phase II |
